Lynx1 Capital Management LP, 10% Owner at TScan Therapeutics, Inc. (TCRX), bought 160,138 shares at $0.90 ($144K) on 2025-12-19, disclosed to the SEC on 2025-12-23.
Open-market purchase of $144k TCRX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.90 | 80,069 | $72K | 50.0% |
| 2 | $0.90 | 80,069 | $72K | 50.0% |
| Total | $0.90 avg | 160,138 | $144K | 100% |
| Filing → |
| KRRO | BUY | 2026-04-02 | $6K | — | Filing → |
| NEUP | BUY | 2025-10-23 | $6.6M | — | Filing → |
| CGEM | BUY | 2025-10-21 | $2.5M | — | Filing → |